Notice NOT-AG-24-097 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-284 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Announcement (NOFO) is to encourage pilot research that is not an immediate precursor to testing a service intervention but is consistent with NIMH priorities for services research. While NIMH now requires use of an experimental therapeutics model for all intervention studies, there is recognition that some mission-relevant areas of services research do not involve clinical trials.

Funding Opportunity PAR-25-283 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Announcement (NOFO) is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities for mental health services research.

Funding Opportunity PAR-25-099 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of a comprehensive and well-defined product development strategy for next-generation treatments for HIV and HIV-associated comorbidities, coinfections and complication and preventive strategies for HIV, as well as facilitating the translation of research findings into drug products that enables submission of an Investigational New Drug (IND) application to the FDA.

Funding Opportunity PAR-25-374 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.

Funding Opportunity RFA-EY-25-002 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to request applications that aim to implement and evaluate multi-level interventions and community engaged research in advancing vision equity. This Notice of Funding Opportunity (NOFO) supports research directed at preventing, reducing, or eliminating disparities in eye and vision health. Applications responding to this NOFO must involve multilevel interventions that simultaneously address vision health conditions and social determinants of health (SDOH) at one or more levels of influence, such as individual, interpersonal, organizational, and community. Research must include a focus on improving vision health in one or more NIH-designated Populations with Health Disparities. Additionally, research must demonstrate meaningful community engagement in the research process.

Funding Opportunity PAR-25-101 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.

Notice NOT-AG-24-086 from the NIH Guide for Grants and Contracts

Notice NOT-MH-25-050 from the NIH Guide for Grants and Contracts

Notice NOT-MH-25-045 from the NIH Guide for Grants and Contracts

Notice NOT-GM-25-017 from the NIH Guide for Grants and Contracts

Notice NOT-GM-25-016 from the NIH Guide for Grants and Contracts

Notice NOT-AA-25-002 from the NIH Guide for Grants and Contracts

Notice NOT-HL-24-036 from the NIH Guide for Grants and Contracts

Notice NOT-HS-25-012 from the NIH Guide for Grants and Contracts

Notice NOT-AI-25-017 from the NIH Guide for Grants and Contracts

Notice NOT-CA-25-007 from the NIH Guide for Grants and Contracts

Notice NOT-DC-25-022 from the NIH Guide for Grants and Contracts

Notice NOT-GM-25-012 from the NIH Guide for Grants and Contracts

Notice NOT-EY-25-003 from the NIH Guide for Grants and Contracts